zantac news - Search News

Reuters on MSN · 1h

GSK shares jump on $2.2 billion Zantac settlement

By Maggie Fick and Yamini Kalia (Reuters) -GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.

The New York Times · 11h

Zantac’s Developer Settles Lawsuits Claiming Cancer Link

GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

16mon MSN

GSK Stock Jumps as UK Drug Giant Resolves Most US Zantac Lawsuits

GSK shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced ...

18h

GSK Reached Agreements With 10 Plaintiff Firms Over Zantac Litigation

GSK agreed to pay $2.2 billion to 10 plaintiff firms over liability cases related to its discontinued heartburn medicine ...

Business Times2h

GSK surges 6.5% after US$2.2 billion Zantac lawsuits settlement

SHARES of British drugmaker GSK rose as much as 6.5 per cent on Thursday (Oct 10), after it agreed to pay up to US$2.2 ...

1hon MSN

UK property market strengthens, but renters face tighter squeeze; GSK’s shares surge after $2.2bn Zantac settlement – business live

Lenders report that default rates on secured loans to UK households increased in Q3 2024 and are expected to increase again ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results